Features of SRSF2-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).

Abstract read

In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marc TöllyMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria.

Klaus GeisslerMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria. geissler.klaus@gmx.at.ORCID http://orcid.org/0000-0003-1921-7034

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The big data derived from major international collaborations now make it possible to validate findings from traditional national patient cohorts in order to demonstrate consistency. In this study, we compared findings in SRSF2-mutated patients of the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with the CMML cohort documented in cBioPortal. It has been consistently shown in both CMML cohorts that SRSF2 mutations are not associated with shorter overall survival and acute myeloid leukemia-free survival. Regarding phenotypic features, it was found that SRSF2 mutations were significantly associated with higher hemoglobin values in the ABCMML and cBioPortal cohorts. The number of platelets was significantly lower in SRSF2-mutated patients in both CMML cohorts, but there were no differences regarding leukocytes and circulating blasts. Data validation using two independent CMML cohorts ensures the quality standards for clinical decision-making.

Indexed as

Leukemia, Myelomonocytic, ChronicMutationSerine-Arginine Splicing FactorsAgedAged, 80 and overAustriaCohort StudiesFemaleHumansMaleMiddle AgedPrognosisSerine-Arginine Splicing FactorsSRSF2 protein, humanAustrian biodatabase for chronic myelomonocytic leukemiacBioPortalChronic myelomonocytic leukemiaMutationsSRSF2

Identifiers

PMID40549056

DOI10.1007/s10354-025-01091-x

PMCPMC12380958

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.